• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢低级别浆液性癌:52例浸润性病例的临床病理分析及一种可能的非浸润性中间病变的鉴定

Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.

作者信息

Ahn Geunghwan, Folkins Ann K, McKenney Jesse K, Longacre Teri A

机构信息

*Department of Pathology, Stanford University School of Medicine, Stanford †Department of Pathology, University of California San Francisco, San Francisco, CA ‡Department of Pathology, Cleveland Clinic, Cleveland, OH.

出版信息

Am J Surg Pathol. 2016 Sep;40(9):1165-76. doi: 10.1097/PAS.0000000000000693.

DOI:10.1097/PAS.0000000000000693
PMID:27487741
Abstract

Low-grade serous carcinoma (LGSC) is an uncommon but distinct histologic subtype of ovarian carcinoma. Although the histologic features and natural history of LGSC have been described in the literature, there is no robust correlative study that has specifically addressed histologic features in correlation with clinical follow-up. To refine the criteria for invasion patterns of LGSC and determine additional clinically pertinent morphologic features of LGSC predisposing to a more aggressive clinical course, the clinicopathologic features of 52 LGSCs were evaluated and compared with those of a large series of serous borderline tumors (SBT), with and without invasive implants. To qualify for LGSC, the tumor needed to demonstrate destructive invasion, nuclear atypia that was mild to moderate at most (grade 1 or 2), and a mitotic index that did not exceed 12 mitoses per 10 high-power fields. On the basis of histologic evaluation, destructive invasion was classified into 7 primary architectural patterns: (1) micropapillary and/or complex papillary; (2) compact cell nests; (3) inverted macropapillae; (4) cribriform; (5) glandular and/or cystic; (6) solid sheets with slit-like spaces; and (7) single cells. Five-year overall survival and disease-free survival for LGSC were 82% (median, 72 mo) and 47% (median, 54 mo), respectively. All the patients with fatal outcome demonstrated tumors showing invasion with predominant patterns of cribriform glands, micropapillae and/or complex papillae, or compact cell nests. Notably, 2 of 9 patients with fatal outcome had only small foci of destructive invasion (2 and 3 mm, respectively) with compact cell nests and cribriform glands as the predominant patterns. There was no statistically significant association between pattern of invasion and disease-free survival. Classic stromal microinvasion, as defined by nondestructive stromal invasion <5 mm was identified in 52% of LGSC and was statistically more frequent in LGSC than in SBT (P<0.001). In 2 LGSCs, there were areas demonstrating an intraluminal solid proliferation of tumor cells with grade 1 or 2 nuclear atypia, which we hypothesize may represent a noninvasive form of LGSC, as similar non-invasive proliferations of morphologically low-grade serous carcinomatous cells were also identified in 8 SBTs, in either solid or compact glandular/papillary formations. One patient with this isolated noninvasive pattern in SBT developed LGSC 40 months after initial operation. LGSC was typically high stage (FIGO stages II to IV, 86%) and bilateral (68%), with multiple foci of invasion (82%). Bilaterality was significantly more common in high-stage disease (P=0.009). LGSC was associated with SBT in 84% of cases, most commonly usual type (27%), followed by cribriform (18%), micropapillary (11%), or mixed cribriform and micropapillary (7%) types; focal micropapillary and/or cribriform features were present in an additional 16%. The presence of intraluminal proliferations of cells resembling LGSC occurring in SBT should prompt additional tumor sampling and assiduous evaluation of implants (if present), as this appears to represent a form of intraepithelial carcinoma, which may be associated with invasion elsewhere.

摘要

低级别浆液性癌(LGSC)是一种罕见但独特的卵巢癌组织学亚型。尽管LGSC的组织学特征和自然史已在文献中有所描述,但尚无专门针对组织学特征与临床随访相关性的有力相关研究。为了完善LGSC浸润模式的标准,并确定LGSC中其他与临床相关的、易导致更具侵袭性临床病程的形态学特征,我们评估了52例LGSC的临床病理特征,并将其与一大系列浆液性交界性肿瘤(SBT)(有或无侵袭性种植灶)的临床病理特征进行了比较。要符合LGSC的诊断标准,肿瘤需表现出破坏性浸润、核异型性至多为轻度至中度(1级或2级),且有丝分裂指数不超过每10个高倍视野12个有丝分裂象。基于组织学评估,破坏性浸润被分为7种主要结构模式:(1)微乳头和/或复杂乳头;(2)紧密细胞巢;(3)倒置大乳头;(4)筛状;(5)腺管状和/或囊性;(6)有裂隙样间隙的实性片层;(7)单个细胞。LGSC的5年总生存率和无病生存率分别为82%(中位数,72个月)和47%(中位数,54个月)。所有死亡患者的肿瘤均表现为以筛状腺体、微乳头和/或复杂乳头或紧密细胞巢为主的浸润模式。值得注意的是,9例死亡患者中有2例仅有小灶性破坏性浸润(分别为2毫米和3毫米),以紧密细胞巢和筛状腺体为主要模式。浸润模式与无病生存率之间无统计学显著关联。按照非破坏性间质浸润<5毫米定义的经典间质微浸润在52%的LGSC中被识别,且在LGSC中比在SBT中在统计学上更常见(P<0.001)。在2例LGSC中,存在肿瘤细胞在管腔内实性增生且核异型性为1级或2级的区域,我们推测这可能代表LGSC的一种非侵袭性形式,因为在8例SBT中也发现了形态学上低级别浆液性癌细胞的类似非侵袭性增生,表现为实性或紧密腺管状/乳头状结构。1例SBT中具有这种孤立非侵袭性模式的患者在初次手术后40个月发生了LGSC。LGSC通常为高分期(国际妇产科联盟(FIGO)分期II至IV期,86%)且双侧发生(68%),有多个浸润灶(82%)。双侧性在高分期疾病中显著更常见(P=0.009)。84%的病例中LGSC与SBT相关,最常见的是普通型(27%),其次是筛状型(18%)、微乳头型(11%)或筛状和微乳头混合型(7%);另外16%存在局灶性微乳头和/或筛状特征。SBT中出现类似LGSC的管腔内细胞增生应促使进行额外的肿瘤取材并仔细评估种植灶(如果存在),因为这似乎代表一种上皮内癌形式,可能与其他部位的浸润有关。

相似文献

1
Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.卵巢低级别浆液性癌:52例浸润性病例的临床病理分析及一种可能的非浸润性中间病变的鉴定
Am J Surg Pathol. 2016 Sep;40(9):1165-76. doi: 10.1097/PAS.0000000000000693.
2
Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.卵巢低级别浆液性癌:对在单一机构进行初次手术的33例病例的临床病理研究
Am J Surg Pathol. 2016 May;40(5):627-35. doi: 10.1097/PAS.0000000000000615.
3
Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.低恶性潜能卵巢浆液性肿瘤(交界性肿瘤)的间质浸润模式:对间质微浸润概念的重新评估
Am J Surg Pathol. 2006 Oct;30(10):1209-21. doi: 10.1097/01.pas.0000213299.11649.fa.
4
Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.卵巢浆液性交界性肿瘤:137例长期随访研究,其中18例具有微乳头模式,20例有微浸润。
Am J Surg Pathol. 2002 Sep;26(9):1111-28. doi: 10.1097/00000478-200209000-00002.
5
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.浆液性交界性肿瘤细分为非典型增生性肿瘤和非浸润性低级别癌的长期行为:一项基于人群的942例临床病理研究
Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.
6
Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.低恶性潜能的卵巢浆液性肿瘤伴淋巴结低级别浆液性癌。
Am J Surg Pathol. 2012 Jul;36(7):955-63. doi: 10.1097/PAS.0b013e31825793e1.
7
Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.卵巢浆液黏液性(宫颈内膜样黏液性及混合细胞型)肿瘤的诊断标准及行为:非典型增生性(交界性)肿瘤、上皮内肿瘤、微浸润癌及浸润癌。
Am J Surg Pathol. 2002 Dec;26(12):1529-41. doi: 10.1097/00000478-200212000-00001.
8
Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.微小浸润将卵巢浆液性交界性肿瘤与1级浸润性癌联系起来。
Gynecol Oncol. 2007 Jul;106(1):44-51. doi: 10.1016/j.ygyno.2007.01.054. Epub 2007 Apr 27.
9
Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors of Low Malignant Potential) Based on Clinical Outcome.基于临床结果对卵巢浆液性交界性肿瘤(低度恶性潜能肿瘤)患者的卵巢外种植进行分类
Am J Surg Pathol. 2016 Sep;40(9):1155-64. doi: 10.1097/PAS.0000000000000692.
10
Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.卵巢浆液性交界性肿瘤中的自身种植:30例病例的临床病理研究——一种需与浆液性腺癌相鉴别的病变
Am J Surg Pathol. 2006 Apr;30(4):457-62. doi: 10.1097/00000478-200604000-00005.

引用本文的文献

1
Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist's perspective.患者来源的类器官作为研究输卵管卵巢癌的模型:病理学家的观点
J Ovarian Res. 2025 Aug 20;18(1):191. doi: 10.1186/s13048-025-01766-4.
2
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.通过药物重新定位革新卵巢癌治疗,实现加速且具成本效益的治疗。
Front Oncol. 2025 Jan 14;14:1514120. doi: 10.3389/fonc.2024.1514120. eCollection 2024.
3
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
原发性卵巢浆液性交界性肿瘤中的KRAS突变与肿瘤复发相关。
Virchows Arch. 2023 Jul;483(1):71-79. doi: 10.1007/s00428-023-03564-z. Epub 2023 May 23.
4
Investigating the suitability of cell lines as models for the major subtypes of epithelial ovarian cancer.研究细胞系作为上皮性卵巢癌主要亚型模型的适用性。
Front Cell Dev Biol. 2023 Feb 13;11:1104514. doi: 10.3389/fcell.2023.1104514. eCollection 2023.
5
Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets.上皮性卵巢癌中的环状RNA:从生物标志物到治疗靶点
Cancers (Basel). 2022 Nov 21;14(22):5711. doi: 10.3390/cancers14225711.
6
Prognosis and Prognostic Factors of Serous Borderline Tumor-Micropapillary Variant: Retrospective Study of 200 Patients with Long-Term Follow-Up.浆液性交界性肿瘤微乳头亚型的预后及预后因素:200例长期随访患者的回顾性研究
J Oncol. 2022 Oct 10;2022:1655422. doi: 10.1155/2022/1655422. eCollection 2022.
7
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.当代II-IV期低级别浆液性卵巢/腹膜癌(LGSOC)女性的初始治疗:复发和无病生存的决定因素
Gynecol Oncol. 2022 Nov;167(2):139-145. doi: 10.1016/j.ygyno.2022.09.005. Epub 2022 Sep 20.
8
Low-Grade Serous Carcinoma of the Ovary: The Current Status.卵巢低级别浆液性癌:现状
Diagnostics (Basel). 2022 Feb 10;12(2):458. doi: 10.3390/diagnostics12020458.
9
Pathologic Classification of Ovarian Cancer.卵巢癌的病理学分类。
Methods Mol Biol. 2022;2424:11-40. doi: 10.1007/978-1-0716-1956-8_2.
10
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.卵巢癌相关腹水富含细胞因子反应性 CD56brightNK 细胞。
Cells. 2021 Jul 6;10(7):1702. doi: 10.3390/cells10071702.